GSK sees commercial opportunity in antimicrobial resistance

GSK sees commercial opportunity in antimicrobial resistance

BIOCENTURY | Pharma stops trials of antibiotic gepotidacin early for efficacy as it deepens commitment to fighting AMR

Full Story